Kezar Life Sciences, Inc. (2KZ.F)
| Previous Close | 0.7400 |
| Open | 0.7250 |
| Bid | 0.7650 x 0 |
| Ask | 0.7900 x 0 |
| Day's Range | 0.7250 - 0.7250 |
| 52 Week Range | 0.6150 - 2.8000 |
| Volume | |
| Avg. Volume | 1,969 |
| Market Cap | 55.814M |
| Beta (5Y Monthly) | 0.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3100 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.75 |
Insider Monkey13 Best Penny Stocks to Buy According to Billionaire Ken Griffin
In this article, we will take a look at the 13 best penny stocks to buy according to billionaire Ken Griffin. To see more such companies, go directly to 5 Best Penny Stocks to Buy According to Billionaire Ken Griffin. The markets were off to an impressive start in 2024, driven by expectations that the […]
Business WireKezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., April 08, 2024--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the company’s Board of Directors granted one employee a nonqualified stock option to purchase 12,000 shares of its common stock with an exercise price of $0.93 per share, which is equal to the closing price of Kezar’s common stock on April 1, 2
Business WireKezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., March 14, 2024--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update.
